Longeveron, Inc. (LGVN)
1.16
+0.06
(+5.45%)
USD |
NASDAQ |
Apr 07, 16:00
1.16
0.00 (0.00%)
After-Hours: 20:00
Longeveron EPS Diluted (Quarterly) : -0.2374 for Dec. 31, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Acadia Healthcare Co., Inc. | -13.02 |
| Charles River Laboratories International, Inc. | -5.619 |
| BioRestorative Therapies, Inc. | -0.3614 |
| Fate Therapeutics, Inc. | -0.2715 |
| CytomX Therapeutics, Inc. | -0.1734 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -5.444M |
| Revenue (Quarterly) | 0.365M |
| Total Expenses (Quarterly) | 5.809M |
| Enterprise Value | 30.13M |
| Gross Profit Margin (Quarterly) | -6.03% |
| Profit Margin (Quarterly) | -1.49K% |
| Earnings Yield | -103.6% |
| Normalized Earnings Yield | -103.63 |